Table 1 Preoperative Baseline and Characteristics

Age (year)

57.08 ± 13.05

59.67 ± 11.71

0.038

Gender (male, %)

98, 79.03%

239, 61.92%

< 0.001

Weight (kg)

66.96 ± 11.89

62.81 ± 11.85

0.001

NYHA class (n, %)

0.001

I

5, 4.04%

9, 2.33%

II

55, 44.35%

109, 28.24%

III

55, 44.35%

228, 59.07%

IV

9, 7.26%

40, 10.36%

EuroSCORE

6.06 ± 2.45

4.54 ± 2.08

< 0.001

 Preoperative LVEF (%)

30.36 ± 4.29

30.99 ± 3.87

0.124

 Preoperative LVDd (cm)

7.11 ± 1.09

6.98 ± 1.05

0.258

 Evaluated PAP (mmHg)

47.85 ± 18.11

48.24 ± 13.66

0.817

 Acute Myocardial infarction

62, 50%

56, 14.51%

< 0.001

 Atrial fibrillation

23, 18.55%

101, 26.17%

0.085

 Diabetes Mellitus

15, 12.10%

34, 8.81%

0.280

 Chronic Renal Failure

3, 2.42%

6, 1.55%

0.525

 Hypertension

33, 26.61%

94, 24.35%

0.613

 Liver Disease

4, 3.23%

14, 3.63%

0.833

 COPD

12, 9.68%

8, 2.07%

< 0.001

 Cancer

2, 1.61%

4, 1.04%

0.604

 Smoking

42, 33.87%

57, 14.77%

< 0.001

 Excessive alcohol

16, 12.90%

28, 7.25%

0.051

 ACEI/ARB use

2, 1.61%

14, 3.63%

0.258

 Ca²⁺-Blocker use

7, 5.64%

11, 2.85%

0.145

 β-blocker use

0

7, 1.81%

0.130

 Statin use

3, 2.42%

8, 2.07%

0.798

 Diuretic use

9

25, 6.48%

0.799

 Aspirin use

0

0

–

 Clopidogrel use

0

7, 1.81%

0.130

 Levosimendan use

0

0

–

 Lyophilized Recombinant Human Brain Natriuretic

0

0

–